Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GLS2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLS2 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic and biophysical assays. |
View GLS2 Products |
| Gene Delivery | GLS2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and metabolic profiling. |
View GLS2 Products |
| Benchmark Ab | Anti-GLS2 Recombinant Antibody High-specificity positive control for Western Blot, IHC, and target engagement assays. |
View GLS2 Products |
| Validator | GLS2 siRNA Set For knockdown verification and functional validation in cell-based assays. |
View GLS2 Products |
| Related Target A | GLS (Glutaminase 1) Critical for counter-screening to ensure isoform selectivity of small molecule inhibitors. |
View GLS Products |
| Related Target B | GLUD1 (Glutamate Dehydrogenase 1) Downstream metabolic node converting GLS2-derived glutamate to alpha-ketoglutarate. |
View GLUD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (GLS2 vs. GLS1) | Highly purified, sequence-verified human GLS2 and GLS1 ortholog proteins available for parallel screening. |
| High-Throughput Enzymatic Screening | Active-site verified recombinant GLS2 with low background, optimized for coupled glutamate-release assays. |
| Cellular Target Engagement | Sequence-verified Lentivirus for robust, stable overexpression of GLS2 in target cancer cell lines. |
| Off-Target & Toxicity Validation | Validated siRNA sets included for precise genetic knockdown controls in phenotypic assays. |
Live GLS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of cancer metabolism has entered a highly refined phase. While first-generation glutaminase inhibitors primarily focused on GLS1 (such as Telaglenastat/CB-839), the distinct role of GLS2 (liver-type glutaminase) in specific malignancies and oxidative stress defense is emerging as a critical therapeutic node. The race for GLS2 therapeutics is intensifying, with major players shifting focus from broad metabolic inhibition to highly selective, isoform-specific small molecule inhibitors and combination therapies.
As the metabolic adaptation of cancer cells under therapeutic stress becomes clearer, targeting GLS2 offers a unique avenue to bypass GLS1-resistance mechanisms. The next wave of R&D is targeting GLS2 in luminal breast cancers, glioblastoma, and specific subpopulations of hepatocellular carcinoma, where GLS2 expression dictates tumor survival and resistance to ferroptosis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Solid Tumors (Luminal Breast Cancer, Glioma) | Selectivity Assay (Need high-purity Mutant vs WT and GLS1 vs GLS2 Proteins) |
| Combination Therapies | Oncology-focused Biopharma | Chemoresistant / Radioresistant Cancers | Target Engagement Validation (Need Lentivirus for stable cell line construction) |
| RNA Therapeutics | Gene Therapy Pioneers | Metabolic Disorders, Specific Hepatomas | Knockdown Verification (Need high-specificity siRNA and validation controls) |